RESEARCH
ABOUT
ABOUT
The BCLC has run major research projects at the clinical level and in the laboratory. Current activity is focused in several aspects:
  • Refinement and improvement of the diagnostic criteria for liver cancer.
  • Improvement of the image evaluation of response to therapy.
  • Improvement of the efficacy of surgical resection and loco regional interventions by the application of combined or sequential therapy.
  • Characterization of the natural history of patients that have failed treatment at different evolutionary stages.
  • Evaluation of novel strategies and agents for the treatment of intermediate or advanced cancer either by investigator led studies or through sponsorship of the industry. Phase 2 and 3 trials in 1st and 2nd line are always ongoing.
  • Development of cell lines to understand the transition along different evolutionary phases with emergence of resistance to treatment.
  • Investigation of genetic and biomarker profile to predict response and identify treatment resistance in humans.
  • Genomic profiling for target identification and patients classification for prognosis and personalised treatment.


Research activity is sponsored through competitive grants or contracts with biomedical industry. Current competitive grants are: 

Forner A. FIS- PI13/01229 " Circulating tumour cells (CTCs) role to predict tumor dissemination in hepatocellular carcinoma".Sponsored by:Instituto de Salud Carlos III (ISCIII) PI13/01229. Duration: 01/10/2013-01/10/2016

Bruix J. Oncologia Hepàtica- Barcelona Clinic Liver Cancer (BCLC). Sponsored by: AGAUR (Generalitat de Catalunya), SGR 233. Duration:  2014-2016

 
Bruix J. FIS – Ref. PI14/00962 “The influence of tumour microenvironment heterogeneity in the human hepatocellular carcinoma (HCC) therapeutic response”. Sponsored by:Instituto de Salud Carlos III (ISCIII). Duration: 2015-2017 

Reig M. FIS- PI15/00145 "Prospective Clinical Evaluation of genetic-immune/inflammatory profile in hepatocellular carcinoma treated with sorafenib to predict tolerance and survival ". Sponsored by:Instituto de Salud Carlos III (ISCIII).